<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; nexium</title>
	<atom:link href="http://www.tapanray.in/tag/nexium/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Will ‘Patent Thicket’ Delay Biosimilar Drug Entry in India?</title>
		<link>http://www.tapanray.in/will-patent-thicket-delay-biosimilar-drug-entry-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=will-patent-thicket-delay-biosimilar-drug-entry-in-india</link>
		<comments>http://www.tapanray.in/will-patent-thicket-delay-biosimilar-drug-entry-in-india/#comments</comments>
		<pubDate>Mon, 22 Apr 2019 00:00:21 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[3d]]></category>
		<category><![CDATA[ABBvie]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[Cyltezo]]></category>
		<category><![CDATA[delay]]></category>
		<category><![CDATA[demand]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[entry]]></category>
		<category><![CDATA[evergreening]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Humira]]></category>
		<category><![CDATA[incremental]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPO]]></category>
		<category><![CDATA[linkage]]></category>
		<category><![CDATA[lobbyists]]></category>
		<category><![CDATA[Losec]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[nexium]]></category>
		<category><![CDATA[Office]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Prilosec]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[section]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Thicket]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9496</guid>
		<description><![CDATA[Do pharma and biotech investors encourage companies indulging in ‘patent thicket?’ This question recently grabbed media headlines. On April 02, 2019, one such report brought out: AbbVie investors are calling for the Chair-CEO power split, flagging the CEO’s USD 4 million bonus payout, fueled &#8230; <a href="http://www.tapanray.in/will-patent-thicket-delay-biosimilar-drug-entry-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/will-patent-thicket-delay-biosimilar-drug-entry-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Power Of Color And Design In Pharma Branding</title>
		<link>http://www.tapanray.in/the-power-of-color-and-design-in-pharma-branding/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-power-of-color-and-design-in-pharma-branding</link>
		<comments>http://www.tapanray.in/the-power-of-color-and-design-in-pharma-branding/#comments</comments>
		<pubDate>Mon, 16 Nov 2015 00:00:18 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[blue]]></category>
		<category><![CDATA[branding]]></category>
		<category><![CDATA[color]]></category>
		<category><![CDATA[design]]></category>
		<category><![CDATA[Dr. Reddy's]]></category>
		<category><![CDATA[DRL]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[nexium]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[power]]></category>
		<category><![CDATA[purple]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Requip]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[viagra]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7274</guid>
		<description><![CDATA[On November 06, 2015, the District Court of Delaware of the United States (US) passed a temporary restraining order barring Dr. Reddy&#8217;s Laboratories (DRL) from selling in the US its generic version of AstraZeneca’s blockbuster anti-ulcerant drug Nexium, with immediate &#8230; <a href="http://www.tapanray.in/the-power-of-color-and-design-in-pharma-branding/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-power-of-color-and-design-in-pharma-branding/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Digital Marketing: Is Pharma Still A Laggard?</title>
		<link>http://www.tapanray.in/digital-marketing-is-pharma-still-a-laggard/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=digital-marketing-is-pharma-still-a-laggard</link>
		<comments>http://www.tapanray.in/digital-marketing-is-pharma-still-a-laggard/#comments</comments>
		<pubDate>Mon, 17 Aug 2015 00:00:16 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[Boehringer Ingelheim]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[Cephalon]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Freebies]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[laggard]]></category>
		<category><![CDATA[Maggi]]></category>
		<category><![CDATA[Maggie]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[Nestle]]></category>
		<category><![CDATA[nexium]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Salford Business School]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCB]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6946</guid>
		<description><![CDATA[‘Brand Marketing’ in the pharmaceutical industry, across the world, has mostly remained tradition bound, despite its rapid embracement of modern state of the art tools and technology in most other areas of the business. Many other industries have been demonstrating &#8230; <a href="http://www.tapanray.in/digital-marketing-is-pharma-still-a-laggard/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/digital-marketing-is-pharma-still-a-laggard/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Moving Up The Generic Pharma Value Chain</title>
		<link>http://www.tapanray.in/moving-up-the-generic-pharma-value-chain/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=moving-up-the-generic-pharma-value-chain</link>
		<comments>http://www.tapanray.in/moving-up-the-generic-pharma-value-chain/#comments</comments>
		<pubDate>Mon, 30 Jun 2014 00:00:06 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[biosimilars]]></category>
		<category><![CDATA[BIPP]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[DBT]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Diovan]]></category>
		<category><![CDATA[DRL]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Fondaparinux]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[GlobaData]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[IMS]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[intas]]></category>
		<category><![CDATA[Ipca]]></category>
		<category><![CDATA[life]]></category>
		<category><![CDATA[Lupin]]></category>
		<category><![CDATA[moving]]></category>
		<category><![CDATA[nexium]]></category>
		<category><![CDATA[Ohm]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reliance]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[SBIRI]]></category>
		<category><![CDATA[science]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Up]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[Valcyte]]></category>
		<category><![CDATA[valsartan]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5565</guid>
		<description><![CDATA[June 2014 underscores a significant development for the generic drug exporters of India. Much-delayed and highly expected launch of generic Diovan (Valsartan) is now on its way, as Ranbaxy has reportedly received US-FDA approval to launch the first generic version of this blood pressure drug &#8230; <a href="http://www.tapanray.in/moving-up-the-generic-pharma-value-chain/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/moving-up-the-generic-pharma-value-chain/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Big Pharma’s Windfall Gain From Indian Pharma’s Loss, Costs American Patients Dear</title>
		<link>http://www.tapanray.in/big-pharmas-windfall-gain-from-indian-pharmas-loss-costs-american-patients-dear/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=big-pharmas-windfall-gain-from-indian-pharmas-loss-costs-american-patients-dear</link>
		<comments>http://www.tapanray.in/big-pharmas-windfall-gain-from-indian-pharmas-loss-costs-american-patients-dear/#comments</comments>
		<pubDate>Thu, 19 Jun 2014 09:23:48 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[Diovan]]></category>
		<category><![CDATA[gain]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[loss]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[nexium]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[quagmire]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[UDFDA]]></category>
		<category><![CDATA[Valcyte]]></category>
		<category><![CDATA[Windfall]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5540</guid>
		<description><![CDATA[According to US-FDA, its ‘Import Bans’ on quality grounds of the drugs manufactured at various Indian facilities, such as, Ranbaxy’s Paonta Sahib, Dewas and Mohali and Toansa plants, were reportedly solely directed at negating the health safety risks of American patients &#8230; <a href="http://www.tapanray.in/big-pharmas-windfall-gain-from-indian-pharmas-loss-costs-american-patients-dear/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/big-pharmas-windfall-gain-from-indian-pharmas-loss-costs-american-patients-dear/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drugs From The Same Indian Plant: Safe For Europe, Unsafe For America, Why?</title>
		<link>http://www.tapanray.in/drugs-from-the-same-indian-plant-safe-for-europe-unsafe-for-america-why/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drugs-from-the-same-indian-plant-safe-for-europe-unsafe-for-america-why</link>
		<comments>http://www.tapanray.in/drugs-from-the-same-indian-plant-safe-for-europe-unsafe-for-america-why/#comments</comments>
		<pubDate>Mon, 09 Jun 2014 00:00:37 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[cGMP]]></category>
		<category><![CDATA[commissioner]]></category>
		<category><![CDATA[conspiracy]]></category>
		<category><![CDATA[Diovan]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[Hamburg]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Lipitor]]></category>
		<category><![CDATA[Margaret]]></category>
		<category><![CDATA[nexium]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[plant]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulators]]></category>
		<category><![CDATA[safe]]></category>
		<category><![CDATA[Sun]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Theory]]></category>
		<category><![CDATA[Toansa]]></category>
		<category><![CDATA[unsafe]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[why]]></category>
		<category><![CDATA[wockhardt]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5493</guid>
		<description><![CDATA[Good number of stories on US-FDA banning several drug manufacturing facilities of major domestic players of India over serious quality related issues, have been doing the rounds since about a year and almost at a regular interval. The quagmire has &#8230; <a href="http://www.tapanray.in/drugs-from-the-same-indian-plant-safe-for-europe-unsafe-for-america-why/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drugs-from-the-same-indian-plant-safe-for-europe-unsafe-for-america-why/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Takeover Magician To Tango Again On A Bold New ‘Sunny’ Tune</title>
		<link>http://www.tapanray.in/the-takeover-magician-to-tango-again-on-a-bold-new-sunny-tune/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-takeover-magician-to-tango-again-on-a-bold-new-sunny-tune</link>
		<comments>http://www.tapanray.in/the-takeover-magician-to-tango-again-on-a-bold-new-sunny-tune/#comments</comments>
		<pubDate>Mon, 14 Apr 2014 00:00:39 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AIOCD]]></category>
		<category><![CDATA[ANDA]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[AWACS]]></category>
		<category><![CDATA[cadila]]></category>
		<category><![CDATA[CBI]]></category>
		<category><![CDATA[cGMP]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[Daiichi]]></category>
		<category><![CDATA[Dilip]]></category>
		<category><![CDATA[Diovan]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[IPM]]></category>
		<category><![CDATA[magic]]></category>
		<category><![CDATA[magician]]></category>
		<category><![CDATA[nexium]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PIL]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sankyo]]></category>
		<category><![CDATA[Shanghvi]]></category>
		<category><![CDATA[Sun]]></category>
		<category><![CDATA[sunny]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[takeover]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[US-FDA]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[wand]]></category>
		<category><![CDATA[wockhardt]]></category>
		<category><![CDATA[Zydus]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5240</guid>
		<description><![CDATA[The consolidation process of the Indian pharmaceutical industry continues in its own pace. Most recently, the homegrown pharma takeover magician is all set to tango yet again with a bold ‘Sunny’ tune. The low profile creator of high value ‘Sun &#8230; <a href="http://www.tapanray.in/the-takeover-magician-to-tango-again-on-a-bold-new-sunny-tune/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-takeover-magician-to-tango-again-on-a-bold-new-sunny-tune/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Loss of Ranbaxy, Gain of Big Pharma…And Two Intriguing Coincidences</title>
		<link>http://www.tapanray.in/loss-of-ranbaxy-gain-of-big-pharmaand-two-intriguing-coincidences/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=loss-of-ranbaxy-gain-of-big-pharmaand-two-intriguing-coincidences</link>
		<comments>http://www.tapanray.in/loss-of-ranbaxy-gain-of-big-pharmaand-two-intriguing-coincidences/#comments</comments>
		<pubDate>Mon, 17 Mar 2014 00:00:17 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Actos]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[CBI]]></category>
		<category><![CDATA[cGMP]]></category>
		<category><![CDATA[coincidences]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[Diovan]]></category>
		<category><![CDATA[double]]></category>
		<category><![CDATA[gain]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Hypothesis]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Lipitor]]></category>
		<category><![CDATA[loss]]></category>
		<category><![CDATA[Machiavellian]]></category>
		<category><![CDATA[murkier]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[nexium]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sun]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[two]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[Whammy]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5096</guid>
		<description><![CDATA[In March 2014, the largest pharma player of India by market capitalization, Sun Pharma, became the latest of the large Indian pharma exporters facing the US-FDA ‘Import Ban’ for drugs manufactured at its Gujarat-based plant. This news came as a &#8230; <a href="http://www.tapanray.in/loss-of-ranbaxy-gain-of-big-pharmaand-two-intriguing-coincidences/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/loss-of-ranbaxy-gain-of-big-pharmaand-two-intriguing-coincidences/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharmaceutical Brand Building in a Changing Scenario: Thinking Outside the Box</title>
		<link>http://www.tapanray.in/pharmaceutical-brand-building-in-a-changing-scenario-thinking-outside-the-box/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharmaceutical-brand-building-in-a-changing-scenario-thinking-outside-the-box</link>
		<comments>http://www.tapanray.in/pharmaceutical-brand-building-in-a-changing-scenario-thinking-outside-the-box/#comments</comments>
		<pubDate>Mon, 18 Feb 2013 00:00:24 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[advair]]></category>
		<category><![CDATA[brands]]></category>
		<category><![CDATA[building]]></category>
		<category><![CDATA[changing]]></category>
		<category><![CDATA[emotional]]></category>
		<category><![CDATA[equity]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Lipitor]]></category>
		<category><![CDATA[mega]]></category>
		<category><![CDATA[nexium]]></category>
		<category><![CDATA[NovoNordisk]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[paradigm]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[shift]]></category>
		<category><![CDATA[Tapan]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=1405</guid>
		<description><![CDATA[In this article, I shall explore unconventional ways of “Building sustainable Pharmaceutical Brands” thinking  outside the box, after quickly taking you through the “Challenges of Change” in the evolving dynamics of  the Indian branded generic market. A paradigm shift has &#8230; <a href="http://www.tapanray.in/pharmaceutical-brand-building-in-a-changing-scenario-thinking-outside-the-box/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharmaceutical-brand-building-in-a-changing-scenario-thinking-outside-the-box/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
